Mirum Pharmaceuticals is rapidly growing as a leader in liver disease treatments, raising its 2026 global sales forecast to $660–$680 million due to strong performance of its drug LIVMARLI. Although recent acquisitions have delayed the company’s cash flow positivity to 2028, its pipeline includes promising drugs like Volixibat, MRM-3379, and Brelovitug, which could become blockbusters. Analysts expect significant earnings growth by 2028, with upcoming clinical trial results and FDA decisions serving as key catalysts for the stock's future performance.
Nigel Farage has been reported to the UK Parliament’s standards watchdog over allegations that he lobbied the Bank of England on cryptocurrency policy in ways that could benefit Christopher Harborne, a major investor in stablecoin issuer Tether who h...
UnitedHealth Group remains a strong long-term investment despite recent operational challenges and price increases. Management targets 13–16% bottom-line growth driven by margin recovery, AI investments, and share buybacks. Current valuations suggest...
MemeCore surged over 42% after the Foundation announced a $10 million strategic buyback program to address a recent 85% price crash. Despite the initial rally, the altcoin fell more than 5% within 24 hours, reflecting ongoing market uncertainty. For ...
Ouster, Inc. raised $200 million, increasing its pro forma cash to about $375 million to support large-scale customer growth and inventory for Physical AI applications. The company has customers planning rapid expansion, with unit growth targets rang...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four equally weighted metrics. Since its inception, it has delivered an average total return of 18.32%, outperform...
